Literature DB >> 23640225

Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation.

Laura Gilardi1, Marzia Colandrea, Stefano Vassallo, Laura Lavinia Travaini, Giovanni Paganelli.   

Abstract

A 42-year-old woman underwent resection of a high-risk melanoma of the right thigh. Adjuvant treatment with ipilimumab was then started within a phase III randomised, double-blind clinical trial. F-FDG PET/CT scan showed intense uptake in mediastinal hilar lymph nodes, bilaterally, and in rectus abdominis muscle. Biopsy at the abdominal wall revealed a chronic granulomatous inflammation. After oral steroid treatment, all the areas of abnormal tracer uptake disappeared. Ipilimumab can induce inflammatory immunomediated reactions that should be taken into account to avoid misinterpretation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23640225     DOI: 10.1097/RLU.0b013e31828da691

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

2.  Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging.

Authors:  Laura Gilardi; Chiara Maria Grana; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-11       Impact factor: 9.236

3.  Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma.

Authors:  Victoria Purcell; Beatrice Preti; Ricardo Fernandes
Journal:  Clin Case Rep       Date:  2022-07-11

Review 4.  Precision Medicine and PET/Computed Tomography in Melanoma.

Authors:  Esther Mena; Yasemin Sanli; Charles Marcus; Rathan M Subramaniam
Journal:  PET Clin       Date:  2017-07-14

Review 5.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

6.  Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.

Authors:  Robert H I Andtbacka; Merrick Ross; Igor Puzanov; Mohammed Milhem; Frances Collichio; Keith A Delman; Thomas Amatruda; Jonathan S Zager; Lee Cranmer; Eddy Hsueh; Lisa Chen; Mark Shilkrut; Howard L Kaufman
Journal:  Ann Surg Oncol       Date:  2016-06-24       Impact factor: 5.344

Review 7.  Imaging Biomarkers in Immunotherapy.

Authors:  Rosalyn A Juergens; Katherine A Zukotynski; Amit Singnurkar; Denis P Snider; John F Valliant; Karen Y Gulenchyn
Journal:  Biomark Cancer       Date:  2016-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.